Gideon Hirschfield
University Health Network, Toronto
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gideon Hirschfield as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06381453 · Belimumab in Autoimmune HepatitisUniversity Health Network, Toronto · recruiting · Autoimmune Hepatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:33 UTC. The ranking covers the 200 most relevant of 34 PubMed records, and a shared surname and initials can bring in a namesake. All 34 on PubMed
- 954 citationsRCR 34.7
- Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.Gastroenterology · 2015485 citationsRCR 17.5
- A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.N Engl J Med · 2024252 citationsRCR 42.1
- A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.Hepatology · 2018242 citationsRCR 10.1
- 233 citationsRCR 8.7
- Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.Gastroenterology · 2014189 citationsRCR 6.5
- 176 citationsRCR 7.3
- A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.J Hepatol · 2020170 citationsRCR 8.5
- 169 citationsRCR 7.3
- Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.Lancet Gastroenterol Hepatol · 2017165 citationsRCR 6.0